Over the past year panCELLa has enhanced its patent position and expanded access to its exclusive FailSafeTM and induced Allogeneic Cell Tolerance (iACT Stealth CellsTM ). panCELLa continues to accelerate cell-based therapies to a broad range of diseases by providing safe therapeutic cell products.
In order to further advance panCELLa’s exclusive safety platforms for cell therapy, Dr. Andras Nagy will chair panCELLa’s inaugural Scientific Advisory Board and facilitate research and development between his academic lab at the Lunenfeld-Tanenbaum Research Institute (LTRI SHS) and panCELLa.
panCELLa’s intent to develop therapeutic products in the immunology, mesenchymal stem cell and pancreatic islet space also led to the creation of two subsidiaries – Ankarys Therapeutics and Implant Therapeutics. These subsidiaries have quickly attracted industry partners seeking to develop novel cell therapy products. Given the rapid growth of these therapeutic companies and as founding directors, Dr. Keating and Dr. Rao have elected to step back from their roles at panCELLa in order to devote greater time to ensuring the continued success and development of these therapeutics.
Dr. Armand Keating will be stepping down from his role at panCELLa so that he may devote greater time to his responsibilities as Chair and President of Ankarys. Similarly, Dr. Mahendra Rao has stepped back from his role as CEO at panCELLa while continuing as CEO of Implant. Dr. Rao will continue as a director on the panCELLa board and serve as PanCELLa’s representative on the boards of Ankarys and Implant. In the meantime, Mark Krembil will assume the role of interim CEO as panCELLa begins the process of hiring a Chief Operating Officer. The expertise and strategic guidance of both doctors will aid immeasurably in the rapid deployment of superior CAR-NK and iPSC MSC therapeutic products.
About Ankarys Therapeutics
Founded in 2020, Ankarys is developing highly potent and safe natural killer (NK) cell therapeutics. Capitalizing on Dr. Armand Keating’s expertise and the exclusive panCELLa platforms these NK cell therapy products are being designed to target blood cancer and solid tumors.
About Implant Therapeutics
Founded in 2020, Implant Therapeutics under the guidance of Dr. Mahendra Rao, is engineering iPSC-MSCs containing panCELLa’s FailSafeTM and iACT Stealth CellTM technologies. These iPSC MSCs are an ideal choice for bone, cartilage and tendon replacement strategies combining the advantages of allogeneic and autologous cells as well as allowing them to be used as ex-vivo gene therapy vehicles. To learn more, visit https://www.implant-rx.com
Founded in 2015, panCELLa is a privately-held early-stage biotechnology firm based on the innovative technology developed in Dr. Andras Nagy’s lab at the Sinai Health System (SHS). panCELLa has created platforms that allow for the development of safe, universal, “off-the-shelf” cell lines. To learn more, visit https://pancella.com.